As per our research report, the global sepsis diagnostics market size was worth USD 1014 million in 2022 and is estimated to be growing at a CAGR of 8.51% to reach USD 1525 million by 2027. The increasing prevalence of the disease and its fatal effects have stimulated its growth.
Sepsis is the body’s reaction to the bacteria, fungal, viral, or plastic infection, leading to the systemic inflammatory response, organ failure, or organ dysfunction. Sepsis is emerging as a leading cause of mortality around the globe. As a result, the market players are launching advanced technological products to ensure sepsis diagnosis at the initial stages. Moreover, companies enter mergers and acquisitions to operate research and development activities and expand nationwide market growth.
As per the reports, some products have already been introduced in the United States in food and drug administration for diagnosis purposes. According to the Centers for disease control and prevention, it is estimated that 1.7 million people suffer from hospital-acquired infections (HAI) every year in the United States. As per the ECDC, 2013, around 4.1 million patients were diagnosed with HAI in Europe. However, developed countries with advanced facilities and fewer sepsis cases have been recorded in the study of more than 7000 patient outcomes using the Early Sense systems. The number of ICU days for transferred cases has decreased by 46%.
Impact of COVID-19 on the global sepsis diagnostics market:
The COVID-19 pandemic had a moderate positive impact on sales of diagnostic products for sepsis. The worldwide spread of Covid-19 and new cases of sepsis in Covid-19 patients have forced the leading healthcare solution suppliers to develop sepsis diagnostic technologies. The pandemic outbreak increases the demand for rapid diagnosis and accelerates the use of equipment, reagents, and assay kits to detect sepsis. The movement restrictions caused by the pandemic delayed people's health examinations, affecting the number of tests performed and the sale of reagents. The current COVID-19 pandemic highlights the risks faced by older people prone to complications such as acute respiratory distress syndrome due to pneumonia, which increases the risk of sepsis. Therefore, there is an increasing need for the early diagnosis of sepsis in patients with COVID-19 infection.
MARKET DRIVERS:
The growth of the global sepsis diagnostic market is anticipated to be driven by factors such as the growing burden of infectious diseases and an increasing number of sepsis incidences globally.
According to thelancet.com, an estimated 48.9 million sepsis cases were identified in 2017, in which 11.0 sepsis-related deaths were recorded. People with weak immune systems and chronic diseases such as diabetes, cancer, and AIDS are vulnerable to contracting sepsis, which is expected to drive market growth. In the US, sepsis amongst hospitalized sufferers is growing by 8.7% each year. It is anticipated that there are more than a million cases of sepsis amongst hospitalized sufferers yearly, driving the need for sepsis tests. The continuous expenditure in the healthcare sector is also boosting its infrastructure, making sepsis tests accessible to more people. Many manufacturers of sepsis diagnosis are expanding their product offerings with point-of-care technology to detect sepsis quickly and reduce the time required for overall diagnosis. BACTEC Plus, BacT / Alert, and BACTEC FX blood culture equipment manufactured by BD Company (USA) are automated microbial detection systems that enable rapid diagnosis of sepsis.
Hospital-received infections are a prime motive of morbidity and mortality worldwide. Urinary tract infections, pneumonia, and sepsis are the most common infections caused in hospitals. The senior population and people suffering from persistent illness are driving the demand for sepsis diagnostic products because they are more prone to hospital-received infections due to their weak immune systems.
Furthermore, the increasing prevalence of antibiotic-resistant bacterial strains and rising concern about the health of the people worldwide and growing healthcare expenditure is projected to improve the market growth. Government incentives and investment expenditure to improve healthcare propel the sepsis diagnostics market during the forecast period.
MARKET RESTRAINTS:
Sepsis is a potentially fatal illness that must be recognized and treated by trained health care professionals as soon as possible. Unfortunately, the global shortage of competent professionals and health workers is a big problem faced by the sepsis diagnostic market. As a result, almost half of the patients with severe sepsis transferred by the hospital system are accompanied by emergency medical care. On the other hand, the shortage of skilled emergency care workers affects all stages of patient care, including raising awareness of sepsis, assessing patients for sepsis diagnostic equipment, and making appropriate treatment decisions.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2021 to 2027 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2027 |
|
Segments Covered |
By Pathogen, Product, Technology, Method, Usability, End-User, Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This market research report on the global sepsis diagnostics market has been segmented and sub-segmented based on the pathogen, product, technology, method, usability, end-user, and region.
Sepsis Diagnostics Market Analysis – By Pathogen:
Based on the pathogen, the bacterial sepsis segment is forecasted to register the leading market share in the global sepsis diagnostics market during the forecast period. Since most patients suffering from blood poisoning are bacterial infections, the bacterial sepsis segment held the most significant share of the global sepsis diagnostics market in 2021. Gram-negative bacteria are the most frequent bacterial sepsis. Therefore, the gram-positive bacterial sepsis segment is anticipated to dominate the market during the forecast period. Extensive research and development activities and favorable regulatory approval of novel solutions are expected to support the segment growth.
Due to the rise of Candida infection resulting in septic poisoning, fungal sepsis should expand at an appealing CAGR. However, this disease comes from fewer viruses and parasites, so this segment accounted for a minimal share in 2020.
Sepsis Diagnostics Market Analysis – By Product:
Based on the product, Blood culture media was estimated to be the largest segment in 2020. It grows more rapidly over the forecast period because physicians know blood culture as the gold standard form and a cost-effective screening method. Most clinicians consider the blood culture media the cost-effective and standard method.
The assay kits and reagents segment will show lucrative growth due to their new diagnostic capability and the implementation of automated testing by significant companies.
Sepsis Diagnostics Market Analysis – By Technology:
Based on technology, the microbiology segment dominated the global market, with the largest share of over 48.5%. This is because microbiological techniques allow the use of media tests to detect and identify microorganisms for the diagnosis of sepsis accurately. In addition, new strategic initiatives by key companies are driving the segment growth. For example, in April 2019, BD launched a new platelet quality control medium, BD BACTEC, to help detect and mitigate the occurrence of sepsis in patients undergoing platelet transfusions.
Sepsis Diagnostics Market Analysis – By Method:
Sepsis Diagnostics Market Analysis – By Usability:
Sepsis Diagnostics Market Analysis – By Region:
Regionally, the North American sepsis diagnostics market occupied the most significant share of the global market in 2021. The region is expected to maintain its lead throughout the forecast period due to its established healthcare infrastructure and the increasing adoption of advanced diagnostic solutions. In addition, the strong presence of major regional companies and supportive redemption frameworks are driving the market growth. The United States holds a significant share in North America. Technological advancements, growing adoption of advanced diagnostic products, and high healthcare expenditure.
The European sepsis diagnostics market is projected to grow significantly from 2022 to 2027. The European market held the second-largest share of revenue in the global market in 2021. High incidence of healthcare expenditure and advanced medical procedures have augmented market growth.
The sepsis diagnostics market in the Asia Pacific is the quickest growing region globally and is predicted to grow at a healthy rate during the forecast period. Improving healthcare infrastructure facilities, the availability of advanced diagnostic products, favorable government initiatives, and the rise in healthcare expenditure influence market growth in this region. In addition, the demand for sepsis diagnostic solutions is increasing in countries with a high prevalence of infectious diseases. The countries like China, Japan, and India significantly contribute to the APAC regional market growth.
The Latin American sepsis diagnostics market is predicted to rise at a CAGR of 8.92% from 2022 to 2027.
The sepsis diagnostics market in the Middle East & Africa was valued at USD 35.36 million in 2022, owing to the growing burden of infectious diseases. It is further projected to grow steadily during the forecast period. The increasing number of sepsis incidences in this region and raising awareness among healthcare people augment market growth.
KEY MARKET PARTICIPANTS AND SHARE INSIGHTS:
Some notable companies operating in the global sepsis diagnostics market are BioMérieux SA, T2 Biosystems Inc., Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc., Abbott Laboratories, and Roche Diagnostics Limited, Becton Dickinson and Company, Bruker Corporation, and Beckman Coulter, Inc.
In April 2018, Curetis NV collaborated with partner Acumen Research Laboratories Pte. Ltd and received approval for Unyvero BCU Cartridge for bloodstream infections in Singapore.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Pathogen
5.1.1 Introduction
5.1.2 Bacterial Sepsis
5.1.2.1 Gram-Negative Bacterial Sepsis
5.1.2.2 Gram-Positive Bacterial Sepsis
5.1.3 Fungal Sepsis
5.1.4 Other Pathogen Infections
5.1.5 Y-o-Y Growth Analysis, By Pathogen
5.1.6 Market Attractiveness Analysis, By Pathogen
5.1.7 Market Share Analysis, By Pathogen
5.2 Product
5.2.1 Introduction
5.2.2 Instruments
5.2.3 Blood Culture Media
5.2.4 Assay Kits & Reagents
5.2.5 Software
5.2.6 Y-o-Y Growth Analysis, By Product
5.2.7 Market Attractiveness Analysis, By Product
5.2.8 Market Share Analysis, By Product
5.3 Technology
5.3.1 Introduction
5.3.2 Microbiology
5.3.3 Molecular Diagnostics
5.3.4 Immunoassays
5.3.5 Flow Cytometry
5.3.6 Other Technologies
5.3.7 Y-o-Y Growth Analysis, By Technology
5.3.8 Market Attractiveness Analysis, By Technology
5.3.9 Market Share Analysis, By Technology
5.4 Method
5.4.1 Introduction
5.4.2 Convential Diagnostics
5.4.3 Automated Diagnostics
5.4.4 Y-o-Y Growth Analysis, By Method
5.4.5 Market Attractiveness Analysis, By Method
5.4.6 Market Share Analysis, By Method
5.5 Usability
5.5.1 Introduction
5.5.2 Laboratory Testing
5.5.3 Point-of-Care Testing
5.5.4 Y-o-Y Growth Analysis, By Usability
5.5.5 Market Attractiveness Analysis, By Usability
5.5.6 Market Share Analysis, By Usability
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Pathogen
6.1.3.3 By Product
6.1.3.4 By Technology
6.1.3.5 By Method
6.1.3.6 By Usability
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Pathogen
6.1.4.3 By Product
6.1.4.4 By Technology
6.1.4.5 By Method
6.1.4.6 By Usability
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Pathogen
6.1.5.3 By Product
6.1.5.4 By Technology
6.1.5.5 By Method
6.1.5.6 By Usability
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 bioMérieux SA
8.1.1 Overview
8.1.2 Pathogen Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 T2 Biosystem Inc
8.3 Cepheid
8.4 Thermo Fisher Scientific Inc.
8.5 Nanosphere Inc
8.6 Abbott Laboratories
8.7 Roche Diagnostics Limited
8.8 Becton, Dickinson and Company
8.9 Bruker Corporation
8.10 Beckman Coulter, Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
FAQ's
The global sepsis diagnostics market size is estimated to be worth USD 1525 million by 2027.
Yes, we have studied and included the COVID-19 impact on the global sepsis diagnostics market in this report.
Based on the pathogen, the bacterial sepsis segment accounted for the largest share of the sepsis diagnostics market in 2021.
BioMérieux SA, T2 Biosystems Inc., Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc., Abbott Laboratories, and Roche Diagnostics Limited, Becton Dickinson and Company, Bruker Corporation, and Beckman Coulter, Inc. are some of the major companies in the sepsis diagnostics market.
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
